Retrobulbar Hemodynamic Effects of Nipradilol in Normal and Normal-Tension Glaucoma Eyes

Fukukita, Mitsushi; Ido, Masashi; Osawa, Syunsuke; Sasoh, Mikio; Furuta, Motoyasu; Ito, Kunio; Sugimoto, Masahiko; Uji, Yukitaka

doi:10.1155/2011/652904

Cited by 3 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies in animal models indicate that nipradilol also has neuroprotective qualities 204–206 (see section 6.3). There are conflicting data regarding translation of these neuroprotective qualities to humans; in comparative studies between nipradilol and timolol, no additional beneficial effects were observed in visual field performance of those taking nipradilol vs. timolol 225226, 227 . However, one study has shown that in addition to lowering IOP, nipradilol increases ocular blood flow in both control and NTG eyes 227 , which suggests that nipradilol may have an advantage in prevention against glaucomatous damage by increasing ocular blood flow to the optic nerve head, over similar topical therapies.…”

Section: The No-gc-1-cgmp Pathway As a Target For Glaucoma Therapeuticsmentioning

confidence: 99%

The nitric oxide-guanylate cyclase pathway and glaucoma

2018

View full text Add to dashboard Cite

Glaucoma is a prevalent optic neuropathy characterized by the progressive dysfunction and loss of retinal ganglion cells (RGCs) and their optic nerve axons, which leads to irreversible visual field loss. Multiple risk factors for the disease have been identified, but elevated intraocular pressure (IOP) remains the primary risk factor amenable to treatment. Reducing IOP however does not always prevent glaucomatous neurodegeneration, and many patients progress with the disease despite having IOP in the normal range. There is increasing evidence that nitric oxide (NO) is a direct regulator of IOP and that dysfunction of the NO-Guanylate Cyclase (GC) pathway is associated with glaucoma incidence. NO has shown promise as a novel therapeutic with targeted effects that: 1) lower IOP; 2) increase ocular blood flow; and 3) confer neuroprotection. The various effects of NO in the eye appear to be mediated through the activation of the GC- guanosine 3:5'-cyclic monophosphate (cGMP) pathway and its effect on downstream targets, such as protein kinases and Ca channels. Although NO-donor compounds are promising as therapeutics for IOP regulation, they may not be ideal to harness the neuroprotective potential of NO signaling. Here we review evidence that supports direct targeting of GC as a novel pleiotrophic treatment for the disease, without the need for direct NO application. The identification and targeting of other factors that contribute to glaucoma would be beneficial to patients, particularly those that do not respond well to IOP-dependent interventions.

show abstract

Section: The No-gc-1-cgmp Pathway As a Target For Glaucoma Therapeuticsmentioning

confidence: 99%

The nitric oxide-guanylate cyclase pathway and glaucoma

2018

View full text Add to dashboard Cite

show abstract

“…В литературе содержатся примерно одинаковые средние гемодинамические параметры кровотока в ГА, ЦАС, ЗКЦА и орбитальных венах: ЦВС, вортикозных венах, верхней глазной вене в норме (табл. 1, 2) [1,7,9,[11][12][13][14][15][16][17][18][19].…”

Section: обзоры литературыunclassified

Possibilities of color Duplex Imaging in the diagnosis of ocular vascular pathology

Киселева¹,

Zaitsev²,

Рамазанова³

et al. 2018

ROJ

View full text Add to dashboard Cite

ä-ð ìåä. íàóê, ïðîôåññîð, íà÷àëüíèê îòäåëà óëüòðàçâóêîâûõ èññëåäîâàíèé Ì.Ñ. Çàéöåâ-ìëàäøèé íàó÷íûé ñîòðóäíèê îòäåëà óëüòðàçâóêîâûõ èññëåäîâàíèé Ê.À. Ðàìàçàíîâà-êàíä. ìåä. íàóê, çàâ åäóþùàÿ îòäåëåíèåì óëüòðàçâóêîâîé äèàãíîñòèêè Ê.Â. Ëóãîâêèíà-êàíä. ìåä. íàóê, íàó÷íûé ñîòðóäíèê îòäåëà óëüòðàçâóêîâûõ èññëåäîâàíèé

show abstract

Color Doppler Imaging Analysis of Ocular Blood Flow Velocities in Normal Tension Glaucoma Patients: A Meta-Analysis

Huang

Lin

et al. 2015

Journal of Ophthalmology

View full text Add to dashboard Cite

Background. To evaluate the potential diagnostic value of CDI of retrobulbar hemodynamic changes in NTG patients. Methods. Relevant publications which included PSV, EDV, and RI of OA, CRA, NPCA, and TPCA in NTG patients and normal controls measured by CDI were retrieved from the Cochrane Central Register of Controlled Trials, PubMed, the ISI Web of Knowledge, and EMBASE from 1990 to 2014. Subgroup analyses were made based on IOP-lowering medications uses. Result. In OA, there was significant decrease of PSV with moderate heterogeneity (P < 0.00001, I 2 = 49%) and significant decrease of EDV with significant heterogeneity (P = 0.0005, I 2 = 87%) in NTG patients. In CRA, similar results of PSV (P < 0.00001, I 2 = 42%) and EDV (P < 0.00001, I 2 = 80%) were detected. Significant decrease of PSV and EDV with significant heterogeneity was also found in both NPCA (P < 0.0001, I 2 = 70%; P < 0.0001, I 2 = 76%; resp.) and TPCA (P < 0.00001, I 2 = 54%; P < 0.00001, I 2 = 65%; resp.). Statistically significant increases of RI were found in CRA (P = 0.0002, I 2 = 89%) and TPCA (P = 0.02, I 2 = 81%) with significant heterogeneities, though RI in OA (P = 0.25, I 2 = 94%) and in NPCA (P = 0.15, I 2 = 86%) showed no statistical changes with significant heterogeneities. Conclusions. Ischemic change of retrobulbar hemodynamics is one of the important manifestations of NTG. Hemodynamic parameters measured by CDI might be potential diagnostic tools for NTG.

show abstract

Retrobulbar Hemodynamic Effects of Nipradilol in Normal and Normal-Tension Glaucoma Eyes

Cited by 3 publications

References 18 publications

The nitric oxide-guanylate cyclase pathway and glaucoma

The nitric oxide-guanylate cyclase pathway and glaucoma

Possibilities of color Duplex Imaging in the diagnosis of ocular vascular pathology

Color Doppler Imaging Analysis of Ocular Blood Flow Velocities in Normal Tension Glaucoma Patients: A Meta-Analysis

Contact Info

Product

Resources

About